Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey

被引：43

作者：

Swartz, Michael D. ^{[1
]}

De Santis, Stacia M. ^{[1
]}

Yaseen, Ashraf ^{[1
]}

Brito, Frances A. ^{[1
]}

Valerio-Shewmaker, Melissa A. ^{[2
]}

Messiah, Sarah E. ^{[3
]}

Leon-Novelo, Luis G. ^{[1
]}

Kohl, Harold W., III ^{[4
,5
]}

Pinzon-Gomez, Cesar L. ^{[1
]}

Hao, Tianyao ^{[1
]}

Zhang, Shiming ^{[1
]}

Talebi, Yashar ^{[1
]}

Yoo, Joy ^{[1
]}

Ross, Jessica R. ^{[1
]}

Gonzalez, Michael O. ^{[1
]}

Wu, Leqing ^{[1
]}

Kelder, Steven H. ^{[4
]}

Silberman, Mark ^{[6
]}

Tuzo, Samantha ^{[6
]}

Pont, Stephen J. ^{[7
]}

Shuford, Jennifer A. ^{[7
]}

Lakey, David ^{[8
]}

Boerwinkle, Eric ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth Houston, Houston, TX 77030 USA

[2] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth Brownsville, Brownsville, TX USA

[3] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth Dallas, Dallas, TX USA

[4] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth Austin, Austin, TX USA

[5] Univ Texas Austin, Coll Educ, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA

[6] Clin Pathol Labs, Austin, TX USA

[7] Texas Dept State Hlth Serv, Austin, TX USA

[8] Univ Texas Syst, Off Hlth Affairs, Austin, TX USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2023年 / 227卷 / 02期

关键词：

SARS-CoV-2; antibodies; COVID-19; antibody duration; NEUTRALIZING ANTIBODIES; KINETICS; PERSISTENCE;

D O I：

10.1093/infdis/jiac167

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A longitudinal model shows that expected antibody response after COVID-19 infection increases for 100 days postinfection, and predicts individuals may remain antibody positive beyond 500 days, depending on age, body mass index, smoking or vaping use, and disease severity. Understanding the duration of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody Response Survey (Texas CARES) with at least 1 nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n = 4553) with 1 to 3 antibody tests over 11 months (1 October 2020 to 16 September 2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days postinfection, and predicts individuals may remain antibody positive from natural infection beyond 500 days depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not).

引用

页码：193 / 201

页数：9

共 33 条

[1] Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19 [J].

Alejo, Jennifer L. ;

Mitchell, Jonathan ;

Chang, Amy ;

Chiang, Teresa P. Y. ;

Massie, Allan B. ;

Segev, Dorry L. ;

Makary, Martin A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (11) :1085-1087

[2] A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States [J].

Alfego, David ;

Sullivan, Adam ;

Poirier, Brian ;

Williams, Jonathan ;

Adcock, Dorothy ;

Letovsky, Stanley .

ECLINICALMEDICINE, 2021, 36

[3]

[Anonymous], BMI

[4] Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection [J].

Crawford, Katharine H. D. ;

Dingens, Adam S. ;

Eguia, Rachel ;

Wolf, Caitlin R. ;

Wilcox, Naomi ;

Logue, Jennifer K. ;

Shuey, Kiel ;

Casto, Amanda M. ;

Fiala, Brooke ;

Wrenn, Samuel ;

Pettie, Deleah ;

King, Neil P. ;

Greninger, Alexander L. ;

Chu, Helen Y. ;

Bloom, Jesse D. .

JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (02) :197-205

[5] Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection [J].

Dan, Jennifer M. ;

Mateus, Jose ;

Kato, Yu ;

Hastie, Kathryn M. ;

Yu, Esther Dawen ;

Faliti, Caterina E. ;

Grifoni, Alba ;

Ramirez, Sydney, I ;

Haupt, Sonya ;

Frazier, April ;

Nakao, Catherine ;

Rayaprolu, Vamseedhar ;

Rawlings, Stephen A. ;

Peters, Bjoern ;

Krammer, Florian ;

Simon, Viviana ;

Saphire, Erica Ollmann ;

Smith, Davey M. ;

Weiskopf, Daniela ;

Sette, Alessandro ;

Crotty, Shane .

SCIENCE, 2021, 371 (6529) :587-+

[6] Covid-19: Delta infections threaten herd immunity vaccine strategy [J].

Dyer, Owen .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 374

[7] Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients [J].

Efrati, Shai ;

Catalogna, Merav ;

Abu Hamed, Ramzia ;

Hadanny, Amir ;

Bar-Chaim, Adina ;

Benveniste-Levkovitz, Patricia ;

Strugo, Refael ;

Levtzion-korach, Osnat .

SCIENTIFIC REPORTS, 2021, 11 (01)

[8] Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects [J].

Ferrari, Davide ;

Di Resta, Chiara ;

Tomaiuolo, Rossella ;

Sabetta, Eleonora ;

Pontillo, Marina ;

Motta, Andrea ;

Locatelli, Massimo .

VACCINE, 2021, 39 (31) :4256-4260

[9] Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset [J].

Figueiredo-Campos, Patricia ;

Blankenhaus, Birte ;

Mota, Catarina ;

Gomes, Andreia ;

Serrano, Marta ;

Ariotti, Silvia ;

Costa, Catarina ;

Nunes-Cabaco, Helena ;

Mendes, Antonio M. ;

Gaspar, Pedro ;

Pereira-Santos, M. Conceicao ;

Rodrigues, Fabiana ;

Condeco, Jorge ;

Escoval, M. Antonia ;

Santos, Matilde ;

Ramirez, Mario ;

Melo-Cristino, Jose ;

Simas, J. Pedro ;

Vasconcelos, Eugenia ;

Afonso, Angela ;

Veldhoen, Marc .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2020, 50 (12) :2025-2040

[10]

Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007

← 1 2 3 4 →